Evaluating the Efficacy and Safety of BMS-986263 in Adults with Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)
Not Recruiting
99 years or below
All
75 participants needed
1 Location
Brief description of study
The purpose of this study is to test the effectiveness (how well the study drug works) and safety of BMS-986263 in participants with compensated cirrhosis from nonalcoholic steatohepatitis (NASH). The study drug BMS-986263, is investigational. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA). Currently, there are no approved drugs for the treatment of NASH with compensated cirrhosis.
Detailed description of study
The purpose of this study is to test the effectiveness (how well the study drug works) and safety of BMS-986263 in participants with compensated cirrhosis from nonalcoholic steatohepatitis (NASH). The study drug BMS-986263, is investigational. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA). Currently, there are no approved drugs for the treatment of NASH with compensated cirrhosis.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research, Cirrhosis, Liver, Nonalcoholic Steatohepatitis, NASH
-
Age: 99 years or below
-
Gender: All
Adults with Compensated Cirrhosis from Nonalcoholic Steatohepatitis (NASH)
Updated on
09 Sep 2024.
Study ID: 850532
